Wei Li, Global Chief Investment Strategist together with Alex Brazier, Deputy Head, Yu Song, Chief China Economist, Paolo Puggioni, Data and Innovation Manager and Michel Dilmanian, Member of Investment Strategy team, all forming part of the BlackRock Investment Institute, share their insights on global economy, markets and geopolitics. Their views are theirs alone and are not intended to be construed as investment advice.

The new year has started with a record COVID surge, renewed restrictions and many people working from home again. The difference with this time: The Omicron strain appears less severe in populations with high vaccination and immunity rates. We see Omicron delaying – and not derailing – the powerful restart of economic activity while potentially adding to supply bottlenecks. We stay overweight equities and eye risks that policymakers or markets misread the current surge in inflation. 

Past performance is not a reliable indicator of current or future results. Indexes are unmanaged and not subject to fees. It is not possible to invest directly in an index. Sources: BlackRock Investment Institute, with data from UK Coronavirus (COVID-19) Dashboard . Notes: Chart shows London COVID-19 cases and hospital admissions compared with their January 2021 peak level. Hospital admission data are adjusted by seven days to account for the lag between cases and admissions

Markets have started the new year on a jittery note, with worries centering on Fed rate rises and policy normalization. We urged investors to stay invested through COVID-related volatility as we believed the strain would ultimately only delay the powerful restart of economic activity that has underpinned a surge in corporate profits. More clarity on Omicron in the past weeks has strengthened our conviction, even as the COVID surge may look frightening. Why? First, vaccines and prior infections have proven effective against severe disease even as their efficacy against Omicron infection has fallen. Second, scientific studies are suggesting Omicron is intrinsically somewhat less severe than previous strains. Third, populations have gained higher immunity as more people have caught COVID or received boosters. All this suggests a surge in cases but a more muted rise in hospitalizations. We view the situation in the recent Omicron hot spot of London  as a harbinger of things to come. Case loads spiraled upward to almost double the previous peak in early 2021 (the red line in the chart). Yet hospital admissions have remained 50% below the earlier highwater mark (the yellow line). 

Both case loads and hospitalizations in London have started to come down, suggesting the worst of the Omicron wave may be over. We expect other areas to follow a similar pattern over the next couple of months. The caveats: Outcomes will likely be worse elsewhere as the UK sports high vaccination, booster and immunity rates. And pressure on hospitals and services in general is set to mount as they already face staff shortages. Check out our COVID-19 tracker for the latest trends.

The key question is how China’s zero-COVID policy will stand up against Omicron. The policy so far has proven effective and enjoyed popular support, but has left China with almost no natural immunity. We expect the country to maintain the policy – at least optically – in this politically important year. This raises the spectre of more restrictions on activity, from targeted measures that keep the economy humming (Shanghai)  to full-scale lockdowns (Xi’an). As a result, we believe downside risks to China’s growth have risen, even as Beijing appears bent on achieving its growth target this year by loosening policy. The big picture on Omicron remains that we see it only delay the powerful global restart. Less growth now means more growth later, in our view. Omicron also may have a silver lining. Its highly infectious nature may turn COVID into an endemic disease similar to the flu as populations build up immunity and annual booster shots keep down the human toll.

Risk assets showed clear concern about the Fed over Omicron last week. Policymakers and markets may misread the unique mix of the restart, a mutating virus, supply-driven inflation and new central bank policies. Our base case: Central banks take their foot off the gas pedal to move away from emergency stimulus. We expect them to live with inflation, rather than hit the brakes by raising rates to restrictive levels. The Fed has signaled three rate rises this year – more than we expected. Markets seem primed to equate higher rates as being negative for equities. We’ve seen this before and don’t agree. What really matters is that the Fed has kept signaling a low sum total of rate hikes, and that didn’t change last week. This historically muted response to inflation should keep real policy rates low, in our view, supporting equities. And not all spikes in long-term yields are the same. Last week’s jump in U.S. Treasury yields was about the Fed signaling a readiness to start shrinking its balance sheet. This could result in a return of term premium that typically demand to hold long-term bonds. But this is not necessarily negative for risk assets but can reflect an investor preference for equities over government bonds. Our bottom line: We prefer equities and would use COVID-related selloffs to add to risk. We are underweight DM government bonds – we see yields gradually heading higher but staying historically low.

Past performance is not a reliable indicator of current or future results. Indexes are unmanaged and do not account for fees. It is not possible to invest directly in an index. Sources: BlackRock Investment Institute, with data from Refinitiv Datastream as of January 7, 2022. Notes: The two ends of the bars show the lowest and highest returns at any point over the last 12-months and the dots represent current 12-month  returns. Emerging market (EM), high yield and global corporate investment grade (IG) returns are denominated in U.S. dollars, and the rest in local currencies. Indexes or prices used are, in descending order: spot Brent crude, MSCI USA Index, MSCI Europe Index, ICE U.S. Dollar Index (DXY), MSCI Emerging Markets Index, Bank of America Merrill Lynch Global High Yield Index, J.P. Morgan EMBI Index, spot gold, Refinitiv Datastream Italy 10-year benchmark government bond index, Bank of America Merrill Lynch Global Broad Corporate Index, Refinitiv Datastream Germany 10-year benchmark government bond index and Refinitiv Datastream U.S. 10-year benchmark government bond index.

Stocks and bonds fell after minutes from the Fed’s December meeting indicated a potentially faster-than-expected policy normalization, including speeding up the timeline for trimming its bond portfolio. The big picture remains that major central banks have indicated a historically muted response to rising inflation. This should keep real yields negative and support equities. We see inflation settling at a level higher than pre-COVID even as pressures from supply bottlenecks ease.

Week Ahead

• Jan.10-17  – China money and credit data; Euro area unemployment rate
• Jan.12 – China and U.S. CPI inflation data
• Jan.14 – U.S. industrial production and University of Michigan sentiment

Investors will get a read on the persistence of U.S. consumer price inflation this week, while Chinese credit data may provide clues on the speed of policy loosening. The powerful economic restart has driven U.S. inflation rates to its highest rate in decades. This means the Federal Reserve has clearly met its average inflation target under its new framework, helping open the door for interest rate rises this year.

BlackRock’s Key risks & Disclaimers:

This material is not intended to be relied upon as a forecast, research or investment advice, and is not a recommendation, offer or solicitation to buy or sell any securities or to adopt any investment strategy. The opinions expressed are as of January 10th, 2022 and may change. The information and opinions are derived from proprietary and non-proprietary sources deemed by BlackRock to be reliable, are not necessarily all-inclusive and are not guaranteed as to accuracy. As such, no warranty of accuracy or reliability is given and no responsibility arising in any other way for errors and omissions (including responsibility to any person by reason of negligence) is accepted by BlackRock, its officers, employees or agents. This material may contain ’forward looking’ information that is not purely historical in nature. Such information may include, among other things, projections and forecasts. There is no guarantee that any forecasts made will come to pass. Reliance upon information in this material is at the sole discretion of the reader.

The information provided here is neither tax nor legal advice. Investors should speak to their tax professional for specific information regarding their tax situation. Investment involves risk including possible loss of principal. International investing involves risks, including risks related to foreign currency, limited liquidity, less government regulation, and the possibility of substantial volatility due to adverse political, economic or other developments. These risks are often heightened for investments in emerging/developing markets or smaller capital markets. 

Issued by BlackRock Investment Management (UK) Limited, authorized and regulated by the Financial Conduct Authority. Registered office: 12 Throgmorton Avenue, London, EC2N 2DL.

MeDirect Disclaimers:

This information has been accurately reproduced, as received from  BlackRock Investment Management (UK) Limited. No information has been omitted which would render the reproduced information inaccurate or misleading. This information is being distributed by MeDirect Bank (Malta) plc to its customers. The information contained in this document is for general information purposes only and is not intended to provide legal or other professional advice nor does it commit MeDirect Bank (Malta) plc to any obligation whatsoever. The information available in this document is not intended to be a suggestion, recommendation or solicitation to buy, hold or sell, any securities and is not guaranteed as to accuracy or completeness.

The financial instruments discussed in the document may not be suitable for all investors and investors must make their own informed decisions and seek their own advice regarding the appropriateness of investing in financial instruments or implementing strategies discussed herein.

If you invest in this product you may lose some or all of the money you invest. The value of your investment may go down as well as up. A commission or sales fee may be charged at the time of the initial purchase for an investment. Any income you get from this investment may go down as well as up. This product may be affected by changes in currency exchange rate movements thereby affecting your investment return therefrom. The performance figures quoted refer to the past and past performance is not a guarantee of future performance or a reliable guide to future performance. Any decision to invest in a mutual fund should always be based upon the details contained in the Prospectus and Key Investor Information Document (KIID), which may be obtained from MeDirect Bank (Malta) plc.